Revlimid (lenalidomide), a new medication that has the potential (in combination with dexamethasone) to extend longevity and slowing down the progression of multiple myeloma, has been approved by Health Canada for patients who have undergone at least one treatment.. This makes the drug one of the few once-daily oral therapies that are available for treating this form of blood cancer effectively. The approval was given on the basis of the results of clinical trials that were published in the New England Journal of Medicine. Revlimid is available in capsules of 15 mg and 25 mg.